secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001558370-23-012106
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor expands board to 8, appoints former Novartis BD executive Philip Gotwals
--------------------------------------------------------------------------------

- Board increased from 7 to 8 directors; Philip Gotwals, Ph.D. elected effective July 21, 2023.
- Gotwals brings nearly 30 years biotech experience, most recently Global Head of BD at Novartis.
- Received initial grant of nonstatutory stock option to purchase 115,000 shares, vesting over 4 years.
- Will not initially serve on any committee; standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023012106/0001558370-23-012106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023012106/capr-20230721x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer